Pfizer Inc
PFE25.470USD
+0.180+0.71%
Handelsschluss 01/09, 16:00（ET）Kurse um 15 Minuten verzögert
144.82BMarktkapitalisierung
14.72KGV TTM
mehr Informationen über Pfizer Inc Unternehmen
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
Pfizer Inc Informationen
BörsenkürzelPFE
Name des UnternehmensPfizer Inc
IPO-datumFeb 22, 2080
CEOBourla (Albert)
Anzahl der mitarbeiter81000
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 22
Addresse66 Hudson Boulevard East
StadtNEW YORK
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl10001-2192
Telefon12127332323
Websitehttps://www.pfizer.com/
BörsenkürzelPFE
IPO-datumFeb 22, 2080
CEOBourla (Albert)
Führungskräfte von Pfizer Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+35552.00%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+12289.00%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+7298.00%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-553.00%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+19457.00%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
+30962.00%
Mr. Aamir Malik
Mr. Aamir Malik
Executive Vice President, Chief US Commercial Officer
Executive Vice President, Chief US Commercial Officer
29.55K
+29174.00%
Ms. Payal Sahni
Ms. Payal Sahni
Executive Vice President, Chief People Experience Officer
Executive Vice President, Chief People Experience Officer
24.85K
+1543.00%
Dr. Scott Gottlieb, M.D.
Dr. Scott Gottlieb, M.D.
Independent Director
Independent Director
10.00K
--
Mr. Cyrus Taraporevala
Mr. Cyrus Taraporevala
Independent Director
Independent Director
10.00K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+35552.00%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+12289.00%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+7298.00%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-553.00%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+19457.00%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
+30962.00%
Umsatzaufteilung
Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Eliquis alliance revenues and direct sales
2.02B
12.10%
Prevnar family
1.74B
10.46%
Vyndaqel family
1.59B
9.55%
Paxlovid
1.23B
7.36%
Comirnaty
1.15B
6.91%
Andere
8.93B
53.62%
Nach RegionUSD
Name
Umsatz
Anteil
United States
10.69B
64.19%
Developed Markets
3.70B
22.19%
Emerging Markets
2.27B
13.61%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Eliquis alliance revenues and direct sales
2.02B
12.10%
Prevnar family
1.74B
10.46%
Vyndaqel family
1.59B
9.55%
Paxlovid
1.23B
7.36%
Comirnaty
1.15B
6.91%
Andere
8.93B
53.62%
Aktionärsstatistik
Aktualisiert: Sun, Nov 16
Aktualisiert: Sun, Nov 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.35%
State Street Investment Management (US)
5.26%
BlackRock Institutional Trust Company, N.A.
5.17%
Geode Capital Management, L.L.C.
2.27%
Norges Bank Investment Management (NBIM)
1.65%
Andere
76.30%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.35%
State Street Investment Management (US)
5.26%
BlackRock Institutional Trust Company, N.A.
5.17%
Geode Capital Management, L.L.C.
2.27%
Norges Bank Investment Management (NBIM)
1.65%
Andere
76.30%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
33.34%
Investment Advisor/Hedge Fund
23.13%
Research Firm
2.99%
Pension Fund
2.47%
Bank and Trust
1.76%
Sovereign Wealth Fund
1.72%
Insurance Company
1.27%
Hedge Fund
0.93%
Holding Company
0.05%
Andere
32.35%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
4669
3.85B
67.65%
-88.11M
2025Q3
4830
3.80B
66.84%
-140.11M
2025Q2
4945
3.85B
67.75%
-89.09M
2025Q1
5074
3.86B
67.90%
-51.97M
2024Q4
5153
3.84B
67.74%
-83.26M
2024Q3
5005
3.85B
67.99%
-51.77M
2024Q2
5026
3.84B
67.75%
-120.77M
2024Q1
5032
3.89B
68.71%
-120.39M
2023Q4
5089
3.97B
70.25%
-96.67M
2023Q3
4952
4.00B
70.89%
-71.80M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
531.51M
9.35%
+833.15K
+0.16%
Sep 30, 2025
State Street Investment Management (US)
299.09M
5.26%
+2.79M
+0.94%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
294.15M
5.17%
+5.26M
+1.82%
Sep 30, 2025
Geode Capital Management, L.L.C.
129.01M
2.27%
+1.54M
+1.20%
Sep 30, 2025
Norges Bank Investment Management (NBIM)
93.65M
1.65%
+5.87M
+6.68%
Jun 30, 2025
Wellington Management Company, LLP
60.46M
1.06%
-16.54M
-21.48%
Sep 30, 2025
State Farm Insurance Companies
57.66M
1.01%
+71.50K
+0.12%
Sep 30, 2025
MFS Investment Management
54.96M
0.97%
-17.80M
-24.46%
Sep 30, 2025
BlackRock Asset Management Ireland Limited
52.35M
0.92%
-2.30M
-4.21%
Sep 30, 2025
BlackRock Investment Management (UK) Ltd.
50.76M
0.89%
+1.88M
+3.85%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Mon, Dec 1
Aktualisiert: Mon, Dec 1
Name
Anteil
VanEck Pharmaceutical ETF
10.43%
First Trust NASDAQ Pharmaceuticals ETF
7.73%
Franklin US Dividend Booster Index ETF
7.39%
First Trust Morningstar Dividend Leaders Index Fund
6.54%
WBI Power Factor High Dividend ETF
4.87%
Invesco Pharmaceuticals ETF
4.84%
Coastal Compass 100 ETF
4.8%
iShares U.S. Pharmaceuticals ETF
4.43%
Amplify Weight Loss Drug & Treatment ETF
4.14%
Roundhill GLP-1 & Weight Loss ETF
3.73%
Mehr Anzeigen
VanEck Pharmaceutical ETF
Anteil10.43%
First Trust NASDAQ Pharmaceuticals ETF
Anteil7.73%
Franklin US Dividend Booster Index ETF
Anteil7.39%
First Trust Morningstar Dividend Leaders Index Fund
Anteil6.54%
WBI Power Factor High Dividend ETF
Anteil4.87%
Invesco Pharmaceuticals ETF
Anteil4.84%
Coastal Compass 100 ETF
Anteil4.8%
iShares U.S. Pharmaceuticals ETF
Anteil4.43%
Amplify Weight Loss Drug & Treatment ETF
Anteil4.14%
Roundhill GLP-1 & Weight Loss ETF
Anteil3.73%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
36.47B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Dec 12, 2025
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 06, 2026 going ex on Jan 23, 2026
Jan 23, 2026
Mar 06, 2026
Jan 23, 2026
Oct 09, 2025
PFE.NB Final Cash Dividend of gross USD 0.43 paid on Dec 01, 2025 going ex on Nov 07, 2025
Nov 07, 2025
Dec 01, 2025
Nov 07, 2025
Jun 25, 2025
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Sep 02, 2025 going ex on Jul 25, 2025
Jul 25, 2025
Sep 02, 2025
Jul 25, 2025
Apr 23, 2025
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Jun 13, 2025 going ex on May 09, 2025
May 09, 2025
Jun 13, 2025
May 09, 2025
Dec 12, 2024
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 07, 2025 going ex on Jan 24, 2025
Jan 24, 2025
Mar 07, 2025
Jan 24, 2025
Oct 09, 2024
PFE.NB Final Cash Dividend of gross USD 0.42 paid on Dec 02, 2024 going ex on Nov 08, 2024
Nov 08, 2024
Dec 02, 2024
Nov 08, 2024
Jun 26, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Sep 03, 2024 going ex on Jul 26, 2024
Jul 26, 2024
Sep 03, 2024
Jul 26, 2024
Apr 24, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Jun 14, 2024 going ex on May 09, 2024
May 10, 2024
Jun 14, 2024
May 09, 2024
Dec 14, 2023
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Mar 01, 2024 going ex on Jan 25, 2024
Jan 26, 2024
Mar 01, 2024
Jan 25, 2024
Oct 04, 2023
PFE.NB Final Cash Dividend of gross USD 0.41 paid on Dec 04, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Dec 04, 2023
Nov 09, 2023
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Pfizer Inc?
Die fünf größten Anteilseigner von Pfizer Inc sind:
The Vanguard Group, Inc. hält 531.51M Aktien, was 9.35% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 299.09M Aktien, was 5.26% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 294.15M Aktien, was 5.17% der Gesamtaktien entspricht.
Geode Capital Management, L.L.C. hält 129.01M Aktien, was 2.27% der Gesamtaktien entspricht.
Norges Bank Investment Management (NBIM) hält 93.65M Aktien, was 1.65% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 531.51M Aktien, was 9.35% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 299.09M Aktien, was 5.26% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 294.15M Aktien, was 5.17% der Gesamtaktien entspricht.
Geode Capital Management, L.L.C. hält 129.01M Aktien, was 2.27% der Gesamtaktien entspricht.
Norges Bank Investment Management (NBIM) hält 93.65M Aktien, was 1.65% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Pfizer Inc?
Die drei wichtigsten Anteilseigner-Typen von Pfizer Inc sind:
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
Wie viele Institutionen halten Anteile an Pfizer Inc (PFE)?
Mit Stand vom 2025Q4 halten 4669 Institutionen Anteile an Pfizer Inc, mit einem Gesamtmarktwert von etwa 3.85B, was 67.65% der Gesamtanteile entspricht. Im Vergleich zum 2025Q3 ist der institutionelle Aktienbesitz um 0.81% gestiegen.
Was ist die größte Einnahmequelle von Pfizer Inc?
Am FY2025Q3 erzielte das Geschäft mit Eliquis alliance revenues and direct sales für Pfizer Inc den höchsten Umsatz in Höhe von 2.02B, was 12.10% des Gesamtumsatzes entspricht.
